Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ANI PHARMACEUTICALS INCANIP · Entity 4638 | SVP, HEAD - ESTABLISHED BRANDS | May 12, 2026 | May 13, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ANI PHARMACEUTICALS INC
Report date May 12, 2026 · Filed May 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 38,271 |
Reported balance
After 2026-05-12 transaction · row 1
1 source rowRow 1 · 2026-05-12 · Sale · Disposed 459 · Balance 38,271 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 12, 2026 Filed May 13, 2026 20:16 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | SaleCommon Stock | 459 | $79.21 | $36,357.39 |
DisclosureSEC source: 0001507496-26-000012 · wk-form4_1778703407.xml · nonDerivative · entry 1 Rowland Thomas Andrew · CIK 0001507496 · SVP, HEAD - ESTABLISHED BRANDS 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,271 Read SEC document |
| March 11, 2026 Filed Mar 13, 2026 21:28 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | SaleCommon Stock | 4,772 | $74.91 | $357,470.52 |
DisclosureSEC source: 0001507496-26-000009 · wk-form4_1773437312.xml · nonDerivative · entry 1 Rowland Thomas Andrew · CIK 0001507496 · SVP, HEAD - ESTABLISHED BRANDS 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,730 Read SEC document |
| February 28, 2026 Filed Mar 2, 2026 22:59 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | Tax withholdingCommon Stock | 628 | $73.90 | $46,409.20 |
DisclosureSEC source: 0001507496-26-000007 · wk-form4_1772492369.xml · nonDerivative · entry 2 Rowland Thomas Andrew · CIK 0001507496 · SVP, HEAD - ESTABLISHED BRANDS 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,502 F2 · kind: Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 2,171 shares of restricted stock, the grant of which was previously reported. Read SEC document |
| February 26, 2026 Filed Mar 2, 2026 22:59 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | GrantCommon Stock | 6,021 | $77.15 | $464,520.15 |
DisclosureSEC source: 0001507496-26-000007 · wk-form4_1772492369.xml · nonDerivative · entry 1 Rowland Thomas Andrew · CIK 0001507496 · SVP, HEAD - ESTABLISHED BRANDS 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,130 F1 · kind: Represents a restricted stock award that will vest in four equal annual installments on the first, second, third and fourth anniversaries of February 26, 2026. Read SEC document |
| February 14, 2026 Filed Feb 17, 2026 21:08 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | Tax withholdingCommon Stock | 485 | $77.36 | $37,519.60 |
DisclosureSEC source: 0001507496-26-000005 · wk-form4_1771362529.xml · nonDerivative · entry 2 Rowland Thomas Andrew · CIK 0001507496 · SVP, HEAD - ESTABLISHED BRANDS 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,109 F2 · kind: Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 1,677 shares of restricted stock, the grant of which was previously reported. Read SEC document |
| February 12, 2026 Filed Feb 17, 2026 21:08 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | Tax withholdingCommon Stock | 566 | $76.70 | $43,412.20 |
DisclosureSEC source: 0001507496-26-000005 · wk-form4_1771362529.xml · nonDerivative · entry 1 Rowland Thomas Andrew · CIK 0001507496 · SVP, HEAD - ESTABLISHED BRANDS 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,594 F1 · kind: Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 1,958 shares of restricted stock, the grant of which was previously reported. Read SEC document |
| February 11, 2026 Filed Feb 13, 2026 21:07 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | Tax withholdingCommon Stock | 1,762 | $76.25 | $134,352.50 |
DisclosureSEC source: 0001507496-26-000003 · wk-form4_1771016868.xml · nonDerivative · entry 1 Rowland Thomas Andrew · CIK 0001507496 · SVP, HEAD - ESTABLISHED BRANDS 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,160 F1 · kind: Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 5,788 performance stock units, the grant of which was previously reported. F2 · balance_after: Includes 128 shares of ANI Pharmaceuticals, Inc. Common Stock that were acquired under the ANI Pharmaceuticals, Inc. Employee Stock Purchase Plan in transactions that were exempt under Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| August 12, 2025 Filed Aug 14, 2025 21:53 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | SaleCommon Stock | 4,975 | $85.71 | $426,407.25 |
DisclosureSEC source: 0001507496-25-000007 · wk-form4_1755208382.xml · nonDerivative · entry 1 Rowland Thomas Andrew · CIK 0001507496 · SVP, HEAD - ESTABLISHED BRANDS 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,794 F1 · shares: The shares were sold in multiple trades at prices ranging from $85.52 to $86.22. The price reported above reflects the weighted average sales price. F2 · balance_after: Includes 304 shares of ANI Pharmaceuticals, Inc. Common Stock that were acquired under the ANI Pharmaceuticals, Inc. Employee Stock Purchase Plan in transactions that were exempt under Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| February 28, 2025 Filed Mar 4, 2025 22:15 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | Tax withholdingCommon Stock | 627 | $61.89 | $38,805.03 |
DisclosureSEC source: 0001507496-25-000004 · wk-form4_1741126494.xml · nonDerivative · entry 1 Rowland Thomas Andrew · CIK 0001507496 · SVP, HEAD - ESTABLISHED BRANDS 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,465 F1 · kind: Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 2,171 shares of restricted stock, the grant of which was previously reported. Read SEC document |
| February 14, 2025 Filed Feb 19, 2025 01:19 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | Tax withholdingCommon Stock | 582 | $58.92 | $34,291.44 |
DisclosureSEC source: 0001507496-25-000002 · wk-form4_1739927941.xml · nonDerivative · entry 3 Rowland Thomas Andrew · CIK 0001507496 · SVP, HEAD - ESTABLISHED BRANDS 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,092 F4 · kind: Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 1,677 shares of restricted stock, the grant of which was previously reported. Read SEC document |
| February 12, 2025 Filed Feb 19, 2025 01:19 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | GrantCommon Stock | 5,222 | $0.00 | $0.00 |
DisclosureSEC source: 0001507496-25-000002 · wk-form4_1739927941.xml · nonDerivative · entry 2 Rowland Thomas Andrew · CIK 0001507496 · SVP, HEAD - ESTABLISHED BRANDS 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,674 F3 · kind: These shares represent performance stock units, which will vest over the applicable performance period based on the achievement of the provided performance targets, as set forth in the governing award agreement, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting. Read SEC document |
| February 12, 2025 Filed Feb 19, 2025 01:19 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | GrantCommon Stock | 7,834 | $0.00 | $0.00 |
DisclosureSEC source: 0001507496-25-000002 · wk-form4_1739927941.xml · nonDerivative · entry 1 Rowland Thomas Andrew · CIK 0001507496 · SVP, HEAD - ESTABLISHED BRANDS 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,452 F1 · kind: Represents a restricted stock award that will vest in four equal annual installments on the first, second, third and fourth anniversaries of February 12, 2025. F2 · balance_after: Includes 449 shares of ANI Pharmaceuticals, Inc. Common Stock that were acquired under the ANI Pharmaceuticals, Inc. Employee Stock Purchase Plan in transactions that were exempt under Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| November 15, 2024 Filed Nov 18, 2024 21:05 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | Tax withholdingCommon Stock | 867 | $56.58 | $49,054.86 |
DisclosureSEC source: 0001507496-24-000006 · wk-form4_1731963909.xml · nonDerivative · entry 1 Rowland Thomas Andrew · CIK 0001507496 · SVP, HEAD - ESTABLISHED BRANDS 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,169 F1 · kind: Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 3,000 shares of restricted stock, the grant of which was previously reported. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.